Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-283.43	-327.27	-340.41	-182.05	-316.38	-184.59
Depreciation & Amortization	13.88	14.2	14.3	10.45	7.44	4.42
Asset Writedown & Restructuring Costs	28.96	13.25	-	-	0.15	0.6
Loss (Gain) From Sale of Investments	-6	0.19	2.89	6.96	3.25	-3.6
Loss (Gain) on Equity Investments	4.49	10.67	12.88	4.09	67.31	0.18
Stock-Based Compensation	54.1	65.95	83.6	80.82	65.26	46.06
Other Operating Activities	-0.19	0.58	2.33	-73.13	3.96	6.45
Change in Accounts Payable	-0.84	-7.5	4.87	-0.77	0.62	-0.99
Change in Unearned Revenue	-0	-0	-0.02	-38.3	38.35	-
Change in Other Net Operating Assets	-28.3	-7.8	-0.95	7.12	14.96	-5.89
Operating Cash Flow	-217.31	-237.73	-220.52	-184.81	-115.09	-137.35
Capital Expenditures	-0.62	-1.52	-5.19	-21.45	-65.96	-50.79
Investment in Securities	88.83	164.81	111.35	185.1	-439.17	214.88
Investing Cash Flow	88.22	163.29	106.16	163.66	-505.12	164.08
Issuance of Common Stock	108.81	95.7	2.95	11.96	633.59	58.96
Financing Cash Flow	111.09	95.7	2.95	11.96	633.59	58.96
Net Cash Flow	-18.01	21.25	-111.41	-9.19	13.38	85.69
Free Cash Flow	-217.93	-239.25	-225.71	-206.26	-181.05	-188.14
Free Cash Flow Margin	-506806.98%	-251841.05%	-144685.90%	-180.79%	-	-
Free Cash Flow Per Share	-1.18	-1.52	-1.58	-1.52	-1.50	-1.86
Levered Free Cash Flow	-111.51	-134.26	-111.74	-85.97	-97.89	-130.06
Unlevered Free Cash Flow	-111.45	-134.26	-111.74	-85.97	-97.89	-130.06
Change in Net Working Capital	10.78	16.34	-5.27	43.17	-56.77	3.5

Source: S&P Capital IQ. Standard template. Financial Sources.